The table below shows Akebia Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$236.20M
$160.18M
$194.62M
$292.48M
$211.65M
$294.64M
Cost of revenue
$39.46M
$63.18M
$74.15M
$85.57M
$150.67M
$296.48M
Gross profit
-
-
-
-
-
-
R&D
$62.36M
$37.65M
$63.08M
$129.99M
$147.85M
$218.49M
SG&A
AKBA annual revenue (10-K history)
Akebia Therapeutics, Inc. reported annual revenue of $236.20M for fiscal year 2025. That is up 47.5% from $160.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.53M (FY 2016) to $236.20M. Figures come from the company's audited annual reports as filed with the SEC.